The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

Treatment with zoledronic acid (Zometa) before onset of skeletal morbidity may lower the risk of skeletal-related events (SRE) and prolong the time to the first SRE in men with bone metastases from ...

Low-dose zoledronic acid appeared safe among older patients with hip fracture and advanced chronic kidney disease.

Protocol amendments made on October 27, 2000, after 254 patients had been enrolled, reduced the dose of zoledronic acid to 4 mg every 6 months and increased the infusion time to 15 minutes, ...

How to Optimize Physicians’ Communication Skills in Cancer Care: Results of a Randomized Study Assessing the Usefulness of Posttraining Consolidation Workshops Purpose: To assess the efficacy and ...

Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.